Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (vol 29, pg 2825, 2023)

被引：1

作者：

Galsky, Matthew D. ^{[1
,2
]}

Daneshmand, Siamak ^{[3
]}

Izadmehr, Sudeh ^{[1
]}

Gonzalez-Kozlova, Edgar ^{[4
]}

Chan, Kevin G. ^{[5
]}

Lewis, Sara ^{[6
]}

El Achkar, Bassam ^{[6
]}

Dorff, Tanya B. ^{[7
]}

Cetnar, Jeremy Paul ^{[8
]}

Neil, Brock O. ^{[9
]}

D'Souza, Anishka ^{[10
]}

Mamtani, Ronac ^{[11
]}

Kyriakopoulos, Christos ^{[12
]}

Jun, Tomi ^{[13
,25
]}

Gogerly-Moragoda, Mahalya ^{[1
]}

Brody, Rachel ^{[2
,14
]}

Xie, Hui ^{[15
]}

Nie, Kai ^{[15
]}

Kelly, Geoffrey ^{[15
]}

Horowitz, Amir ^{[2
,16
]}

Kinoshita, Yayoi ^{[14
]}

Ellis, Ethan ^{[17
,18
]}

Nose, Yohei ^{[16
]}

Ioannou, Giorgio ^{[16
]}

Cabal, Rafael ^{[16
]}

Del Valle, Diane M. ^{[16
]}

Haines, G. Kenneth ^{[19
]}

Wang, Li ^{[1
,20
]}

Mouw, Kent W. ^{[21
]}

Samstein, Robert M. ^{[22
]}

Mehrazin, Reza ^{[23
]}

Bhardwaj, Nina ^{[2
,15
,16
]}

Yu, Menggang ^{[24
]}

Zhao, Qianqian ^{[24
]}

Kim-Schulze, Seunghee ^{[2
,15
,16
]}

Sebra, Robert ^{[2
,17
,18
]}

Zhu, Jun ^{[1
,20
]}

Gnjatic, Sacha ^{[2
,15
,16
]}

Sfakianos, John ^{[23
]}

Pal, Sumanta K. ^{[7
]}

机构：

[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[3] Keck Sch Med USC, Dept Urol, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[4] Icahn Sch Med Mt Sinai, Dept Oncol Sci, Tisch Canc Inst, New York, NY 10029 USA

[5] City Hope Comprehens Canc Ctr, Dept Urol, Duarte, CA USA

[6] Icahn Sch Med Mt Sinai, Dept Radiol, Tisch Canc Inst, New York, NY 10029 USA

[7] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA

[8] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA

[9] Univ Utah, Dept Urol, Salt Lake City, UT USA

[10] Keck Sch Med USC, Div Hematol & Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[11] Univ Penn, Abramson Canc Ctr, Div Hematol & Med Oncol, Philadelphia, PA 19104 USA

[12] Univ Wisconsin, Div Hematol & Med Oncol, Carbone Canc Ctr, Madison, WI USA

[13] Genentech Inc, San Francisco, CA USA

[14] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pathol, New York, NY 10029 USA

[15] Icahn Sch Med Mt Sinai, Human Immune Monitoring Ctr, New York, NY 10029 USA

[16] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA

[17] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA

[18] Icahn Sch Med Mt Sinai, Icahn Inst Data Sci & Genom Technol, New York, NY 10029 USA

[19] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based, New York, NY 10029 USA

[20] Gene Dx, Stamford, CT USA

[21] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA

[22] Icahn Sch Med Mt Sinai, Dept Radiat Oncol, Tisch Canc Inst, New York, NY 10029 USA

[23] Icahn Sch Med Mt Sinai, Dept Urol, Tisch Canc Inst, New York, NY 10029 USA

[24] Univ Wisconsin, Carbone Canc Ctr, Dept Biostat & Med Informat, Madison, WI USA

[25] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 04期

关键词：

D O I：

10.1038/s41591-024-02814-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：1211 / 1211

页数：1

共 50 条

[41] Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial (vol 37, pg 44, 2019)
Coen, John J.
Zhang, Peixin
Saylorv, Philip J.
Lee, Cheryl T.
Wu, Chin-Lee
Parker, William
Lautenschlaeger, Timothy
Zietman, Anthony L.
Efstathiou, Jason A.
Jani, Ashesh B.
Kucuk, Omer
Souhami, Luis
Rodgers, Joseph P.
Sandler, Howard M.
Shipley, William U.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (11) : 1309 - 1309
[42] Combined Chemoradiation Therapy With Twice-Weekly Gemcitabine and Cisplatin for Organ Preservation in Muscle-Invasive Bladder Cancer: Long-Term Results of a Phase 1 Trial
Azria, David
Riou, Olivier
Rebillard, Xavier
Thezenas, Simon
Thuret, Rodolphe
Fenoglietto, Pascal
Pouessel, Damien
Culine, Stephane
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04): : 853 - 859
[43] Outcomes of patients following dose-dense neoadjuvant chemotherapy for muscle-invasive bladder cancer: Implications for organ-sparing strategies.
Dumont, Clement
Gauthier, Helene
Mongiat-Artus, Pierre
Masson-Lecomte, Alexandra
Desgrandchamps, Francois
Culine, Stephane
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[44] A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy
Guo, Yupeng
Dong, Jing
Ji, Tao
Li, Xiaoxia
Rong, Shengzhong
Guan, Hongjun
AGING-US, 2022, 14 (23): : 9715 - 9729
[45] Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
Balar, Arjun Vasant
Milowsky, Matthew I.
O'Donnell, Peter H.
Alva, Ajjai Shivaram
Kollmeier, Marisa
Rose, Tracy L.
Pitroda, Sean
Kaffenberger, Samuel D.
Rosenberg, Jonathan E.
Francese, Kaitlyn
Hochman, Tsivia
Goldberg, Judith D.
Griglun, Sarah
Leis, Dayna
Steinberg, Gary D.
Wysock, James
Schiff, Peter B.
Sanfilippo, Nicholas J.
Taneja, Samir
Huang, William C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[46] A phase 2 trial of neoadjuvant futibatinib plus durvalumab for cisplatin-ineligible patients with FGFR overexpressing muscle-invasive bladder cancer.
Yang, Yuanquan
Jain, Rohit K.
Gupta, Shilpa
Tsung, Irene
Gopalakrishnan, Dharmesh
Gheeya, Jinesh S.
Wei, Lai
Satturwar, Swati
Parwani, Anil
Collier, Katharine A.
Pohar, Kamal S.
Sundi, Debasish
Lee, Cheryl T.
Li, Zihai
Roychowdhury, Sameek
Mortazavi, Amir
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS899 - TPS899
[47] Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study
Han, Sujun
Ji, Zhigang
Jiang, Junhui
Fan, Xinrong
Ma, Qi
Hu, Linjun
Zhang, Wen
Ping, Hao
Wang, Jiansong
Xu, Wanhai
Shi, Benkang
Wang, Wei
Wang, Haifeng
Wang, Honglei
Chen, Shouzhen
Hu, Hailong
Guo, Jianming
Zhang, Shen
Jiang, Shuai
Zhou, Quan
Xing, Nianzeng
CANCER MEDICINE, 2023, 12 (11): : 12106 - 12117
[48] Neoadjuvant nivolumab (N) plus /- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
Guercio, Brendan John
Pietzak, Eugene J.
Brown, Samantha
Chen, Jie-Fu
Peters, Vanessa
Regazzi, Ashley Marie
Aggen, David Henry
Donahue, Timothy F.
Goh, Alvin C.
Cha, Eugene K.
Donat, S. Machele
Dalbagni, Guido
Bochner, Bernard H.
Funt, Samuel Aaron
Bajorin, Dean F.
Iyer, Gopa
Ostrovnaya, Irina
Al-Ahmadie, Hikmat A.
Rosenberg, Jonathan E.
Teo, Min Yuen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[49] Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
de Ruiter, Ben-Max
van Hattum, Jons W.
Lipman, Djoeri
de Reijke, Theo M.
van Moorselaar, R. Jeroen A.
van Gennep, Erik J.
Piet, A. H. Maartje
Donker, Mila
van der Hulle, Tom
Voortman, Jens
Oddens, Jorg R.
Hulshof, Maarten C. C. M.
Bins, Adriaan D.
EUROPEAN UROLOGY, 2022, 82 (05) : 518 - 526
[50] Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712A Randomized Phase II Trial
Coen, John J.
Zhang, Peixin
Saylor, Philip J.
Lee, Cheryl T.
Wu, Chin-Lee
Parker, William
Lautenschlaeger, Timothy
Zietman, Anthony L.
Efstathiou, Jason A.
Jani, Ashesh B.
Kucuk, Omer
Souhami, Luis
Rodgers, Joseph P.
Sandler, Howard M.
Shipley, William U.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (01) : 44 - +

← 1 2 3 4 5 →